Unclassified
Download 3.47 Mb. View original pdf
|
600-85, KSARNG, Substance Abuse Prevention & Control, 2007 Jun 1(2)
| 4 – 7. Deployed drug testing a. Commanders will maintain their substance abuse programs to the maximum extent practical while deployed or on contingency missions. A leader’s responsibility to deter illegal drug use and identify problematic substance users does not stop during deployments. On the contrary, given the nature of operations and the potential presence of live ammunition, explosives, and hostile forces, the impact of ignoring this responsibility is serious and irreversible. b. In areas where Soldiers receive hostile fire pay, O level or higher commanders can authorize temporary suspension or reduction of random drug testing for specific subordinate elements based on METT – TC and/or safety and security issues. c. Commanders will not endanger Soldiers safety and security in hostile fire areas solely to conduct drug testing. d. All company and larger units, to include mobilized USAR and ARNG units, will mobilize and deploy with at least two trained UPLs and enough drug testing supplies to meet testing requirement throughout the deployment or contingency mission. Units smaller than company strength will receive drug testing support from the next higher unit in the chain of command. As needed, rear detachments will support forward units. e. The BACs are assigned for selected deployment areas by special instructions. The senior commander for each deployed unit that is assigned abase area code (BAC) will appoint abase area code manager (BACM) to manage the ASAP for the command and maintain liaison with higher commands and the ASAP. A BACM must be in the rank of a senior NCO or officer (E or above qualifications for BACM are equivalent to that for DTCs (see para 9 – 5). If a member of another service is appointed to BACM duty, the appointing authority or security manager must provide statements justifying the appointee’s qualifications and clearance verification to ARD ASAP for processing of access to sensitive DoD and Army drug testing data. f. The BACM will (1) Retrieve UA test results for the command on a regular basis from the designated FTDTL Web portal, and forward the results via a secure means to unit commanders and MROs, as appropriate. (2) Coordinate with the command’s MRO to obtain their review of those results that could be the result of a legitimate prescription. The BACM will forward the MRO’s decision to the unit commander and enter it in DAMIS. The BACMs in deployed areas will provide positive results for illicit substances to their supporting CID office in theater. Positive UA results on rehabilitation tests will not be released to CID/MP. Positive UA results that require a MRO evaluation will only be released to CID/MP if the MRO determines the results to be illegitimate use. Results determined to be legitimate medical use will not be released. (3) Monitor drug testing rates, trends, specimen discrepancy rates, and MRO delinquency rates. (4) Provide reports, as requested. (5) Monitor UPL certification. (6) Maintain ASAP files in accordance with AR 25 – 400 – 2. g. The MTF commanders in deployed areas who have been assigned a BAC will (1) Appoint in writing enough MROs to review presumptive positive drug test results for the drugs determined by MEDCOM as requiring a medical review. (2) Coordinate with MEDCOM for MRO training and certification for appointed MROs if they are not certified to perform the duties. (3) Monitor MRO workloads and coordinate MRO-related issues with commanders and the BACMs. h. Installation ASAPs will provide drug testing supplies as required to deploying units with enough supplies. Deployed units will order supplies through the supply system. i. The BACMs of deployed units will forward test results for redeployed units to the respective home or mobilization station ASAP managers. Mobilization station ASAP managers will forward the test results for demobilized units to the respective state DTC or MSC ASAP managers. Download 3.47 Mb. Share with your friends:
|